What should we hope to achieve when treating rheumatoid arthritis?
作者信息
Scott D L, Spector T D, Pullar T, McConkey B
机构信息
Department of Rheumatology, St. Bartholomew's Hospital, London.
出版信息
Ann Rheum Dis. 1989 Mar;48(3):256-61. doi: 10.1136/ard.48.3.256.
Abstract
摘要
相似文献
1
What should we hope to achieve when treating rheumatoid arthritis?治疗类风湿性关节炎时我们希望达到什么目标？
Ann Rheum Dis. 1989 Mar;48(3):256-61. doi: 10.1136/ard.48.3.256.
2
Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial.强化管理能否提高中度类风湿性关节炎患者的缓解率？（TITRATE试验）：一项随机对照试验的研究方案。
Trials. 2017 Dec 8;18(1):591. doi: 10.1186/s13063-017-2330-8.
3
Treating interstitial lung disease in rheumatoid arthritis - the embers of hope.治疗类风湿关节炎中的间质性肺病——希望之火
Rheumatology (Oxford). 2020 Dec 1;59(12):3589-3590. doi: 10.1093/rheumatology/keaa516.
4
Re: Goodacre and Goodacre. Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication.
Rheumatology (Oxford). 2004 Dec;43(12):1594; author reply 1594. doi: 10.1093/rheumatology/keh402.
5
Restrictions on the use of higher cost drugs for rheumatoid arthritis in England: Surveys of Clinical Commissioning Groups; prescribers.英格兰对类风湿性关节炎高成本药物使用的限制：临床委托小组；开处方者的调查。
Musculoskeletal Care. 2023 Sep;21(3):943-946. doi: 10.1002/msc.1767. Epub 2023 Apr 24.
6
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study.英国英格兰和威尔士医疗服务不足患者群体中类风湿关节炎生物制剂和靶向合成改善病情抗风湿药起始治疗的相关因素：一项全国队列研究
Lancet Rheumatol. 2025 Jan;7(1):e44-e54. doi: 10.1016/S2665-9913(24)00221-2. Epub 2024 Oct 16.
7
The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease.可溶性肿瘤坏死因子受体依那西普：治疗自身免疫性风湿疾病的新策略。
Drugs Today (Barc). 2004 Apr;40(4):281-324. doi: 10.1358/dot.2004.40.4.820078.
8
Early intervention with disease-modifying therapy for rheumatoid arthritis: where do the delays occur?类风湿关节炎疾病改善治疗的早期干预：延迟发生在何处？
Rheumatology (Oxford). 2002 Aug;41(8):953-5; author reply 955. doi: 10.1093/rheumatology/41.8.953.
9
[The golden age of rheumatoid arthritis treatment].[类风湿关节炎治疗的黄金时代]
Rev Med Inst Mex Seguro Soc. 2014 Mar-Apr;52(2):126-7.
10
[Leflunomide plus methotrexate. Hope for patients with rheumatoid arthritis].
MMW Fortschr Med. 2001 Aug 23;143(33-34):56-7.
引用本文的文献
1
Citation analysis did not provide a reliable assessment of core outcome set uptake.引文分析并未对核心结局指标集的采用情况提供可靠评估。
J Clin Epidemiol. 2017 Jun;86:153-159. doi: 10.1016/j.jclinepi.2017.03.003. Epub 2017 Mar 23.
2
A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.类风湿关节炎患者在第一年接受早期改善病情抗风湿药治疗时反应良好，预示着随访期间病情缓解。
Ann Rheum Dis. 2005 Jan;64(1):38-43. doi: 10.1136/ard.2003.014928. Epub 2004 May 6.
3
Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage.一组早期类风湿性关节炎患者的十年预后：健康状况、疾病进程及损害
Ann Rheum Dis. 2002 Dec;61(12):1055-9. doi: 10.1136/ard.61.12.1055.
4
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands.早期类风湿关节炎的积极治疗：一项随机对照试验。代表荷兰乌得勒支风湿研究基金会。
Ann Rheum Dis. 2000 Jun;59(6):468-77. doi: 10.1136/ard.59.6.468.
5
Sex hormones and the risk of osteoarthritis in women: epidemiological evidence.性激素与女性骨关节炎风险：流行病学证据
Ann Rheum Dis. 1996 Sep;55(9):673-6. doi: 10.1136/ard.55.9.673.
6
Evaluating drugs in rheumatoid arthritis.评估类风湿关节炎的药物。
Ann Rheum Dis. 1989 Sep;48(9):790-1. doi: 10.1136/ard.48.9.790.
7
Disease remission in rheumatoid arthritis.类风湿关节炎的疾病缓解
Ann Rheum Dis. 1989 Nov;48(11):966-7. doi: 10.1136/ard.48.11.966.
8
Disease assessment in rheumatoid arthritis.类风湿关节炎的疾病评估
Ann Rheum Dis. 1989 Nov;48(11):962. doi: 10.1136/ard.48.11.962-a.
9
Assessment of rheumatoid arthritis.类风湿关节炎的评估
Ann Rheum Dis. 1990 Mar;49(3):201. doi: 10.1136/ard.49.3.201-b.
10
Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow?类风湿关节炎的病情改善药物：是昨日之治疗，还是明日之治疗？
Br J Clin Pharmacol. 1990 Oct;30(4):501-10. doi: 10.1111/j.1365-2125.1990.tb03807.x.
本文引用的文献
1
Report of a three-year study on the systemic and articular indexes in rheumatoid arthritis; theoretic and clinical considerations.类风湿关节炎全身及关节指标的三年研究报告；理论与临床思考
Arthritis Rheum. 1958 Dec;1(6):505-22. doi: 10.1002/art.1780010604.
2
Measuring health status in arthritis. The arthritis impact measurement scales.评估关节炎的健康状况。关节炎影响测量量表。
Arthritis Rheum. 1980 Feb;23(2):146-52. doi: 10.1002/art.1780230203.
3
Measurement of patient outcome in arthritis.关节炎患者预后的测量
Arthritis Rheum. 1980 Feb;23(2):137-45. doi: 10.1002/art.1780230202.
4
Preliminary criteria for clinical remission in rheumatoid arthritis.类风湿关节炎临床缓解的初步标准。
Arthritis Rheum. 1981 Oct;24(10):1308-15. doi: 10.1002/art.1780241012.
5
The assessment of disease activity in rheumatoid arthritis using a multivariate analysis.使用多变量分析评估类风湿性关节炎的疾病活动度。
Rheumatol Rehabil. 1981 Feb 1;20(1):14-7. doi: 10.1093/rheumatology/20.1.14.
6
Toward an understanding of patient outcome measurement.迈向对患者预后测量的理解。
Arthritis Rheum. 1983 Jun;26(6):697-704. doi: 10.1002/art.1780260601.
7
Brain death in three neurosurgical units.三个神经外科单元中的脑死亡
Br Med J (Clin Res Ed). 1981 Feb 14;282(6263):533-9. doi: 10.1136/bmj.282.6263.533.
8
Cause of death in rheumatoid arthritis.类风湿关节炎的死因
Br J Rheumatol. 1984 May;23(2):92-9. doi: 10.1093/rheumatology/23.2.92.
9
Progression of radiological changes in rheumatoid arthritis.类风湿关节炎的放射学改变进展
Ann Rheum Dis. 1984 Feb;43(1):8-17. doi: 10.1136/ard.43.1.8.
10
The natural history of rheumatoid arthritis: a fifteen year follow-up study. The prognostic significance of features noted in the first year.类风湿关节炎的自然病史：一项十五年随访研究。第一年所记录特征的预后意义。
Clin Rheumatol. 1984 Mar;3(1):11-20. doi: 10.1007/BF02715690.
Zotero 插件